Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1256

Telisotuzumab

Home » Telisotuzumab

Background of Telisotuzumab

c-Met is a transmembrane receptor tyrosine kinase that is encoded by the MET proto-oncogene and activated upon binding to the hepatocyte growth factor. Dysregulation of c-Met is observed in several types of cancer, including overexpression in approximately 50% of NSCLC. Telisotuzumab vedotin (ABBV-399; Teliso-V) is a first-in-class antibody-drug conjugate (ADC) that uses a cleavable linker to combine a recombinant c-Met–targeting humanized monoclonal antibody (ABT-700) and monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization.

Specifications

Catalog Number:
KB-1256
Antibody Name:
Telisotuzumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
MET
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20C to -80C; Stored at 2-8C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ma PC, Tretiakova MS, MacKinnon AC, et al.: Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47:1025-1037, 2008.
  2. Heist RS, Motwani M, Barlesi F, et al.: c-Met expression and response to telisotuzumab vedotin (Teliso-v) in patients with non-small cell lung cancer. J Clin Oncol 37:9023-90123, 2019.
  3. Camidge DR, Goldman JW, Cole GW, et al.: Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort. Ann Oncol 31:S894, 2020.